We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Assess the Safety and Effectiveness of the Penumbra System

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00334061
First Posted: June 6, 2006
Last Update Posted: July 29, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Penumbra Inc.
  Purpose

This clinical evaluation is a prospective, single-arm, multi-center trial.

The purpose of this clinical evaluation is to assess the safety and effectiveness of the Penumbra System in the revascularization of patients presenting with acute ischemic stroke secondary to intracranial, large vessel, occlusive disease.


Condition Intervention Phase
Stroke Device: Penumbra System Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of the Penumbra™ Stroke System in the Revascularization of Patients With Acute Ischemic Stroke Secondary to Intracranial Large Vessel Occlusive Disease

Further study details as provided by Penumbra Inc.:

Primary Outcome Measures:
  • Percentage of Participants With Revascularization of the Occluded Target Vessel [ Time Frame: 6-Month Post-Procedure ]
  • Percentage of Participants With Device-Related and Procedure-Related Serious Adverse Events [ Time Frame: 6-Month Post-Procedure ]

Secondary Outcome Measures:
  • Percentage of Participants With Either a 4-Point Improvement on the National Institutes of Health Stroke Scale (NIHSS) at Discharge or a Modified Rankin Scale (mRS) Score of ≤ 2 at 30 Days After Treatment [ Time Frame: Discharge or 30-Days Post-Procedure ]
  • Percentage of Participants With a Modified Rankin Scale (mRS) Score of ≤ 2 at 90 Days Post Treatment [ Time Frame: 90-Day ]
  • Percentage of Participants With All Cause Mortality [ Time Frame: 90-Days Post-Treatment ]
  • Percentage of Participants With Symptomatic Hemorrhage [ Time Frame: 24-Hour Post-Procedure ]

Enrollment: 125
Study Start Date: June 2006
Study Completion Date: November 2007
Primary Completion Date: June 2007 (Final data collection date for primary outcome measure)
Detailed Description:

Purpose:

The purpose of this clinical evaluation is to assess the safety and effectiveness of the Penumbra System in the revascularization of patients presenting with acute ischemic stroke secondary to intracranial, large vessel, occlusive disease. Up to 125 evaluable patients will be enrolled in the study.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 79 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical signs consistent with acute ischemic stroke
  • 18 to 79 years of age
  • Neurological deficit resulting in an NIH Stroke Scale (NIHSS) score > 8
  • TIMI 0 or TIMI I flow in vessels accessible to the Penumbra System
  • Signed informed consent
  • Present within 8 hours of stroke symptom onset; ineligible or refractory to intravenous tissue plasminogen activator (t-PA) therapy if presenting within 3 hours of symptom onset.

Exclusion Criteria:

  • Evidence of rapidly improving neurological signs of stroke at time of enrollment
  • NIHSS > 30 or coma
  • Females who are pregnant
  • Vessel tortuosity too difficult to allow endovascular access
  • Known hemorrhagic diathesis, coagulation deficiency, or on oral anticoagulant therapy with an International Normalized Ratio (INR) > 3.0
  • Partial thromboplastin time (PTT) greater than 2 times the lab normal
  • Admission platelets < 30,000
  • Pre-existing neurological or psychiatric disease that could confound the study results
  • Known severe allergy to contrast media
  • Uncontrolled hypertension
  • Computed tomography (CT) evidence of significant mass effect with a midline shift
  • CT reveals evidence of large hypodensity region > 1/3 of the middle cerebral artery territory
  • CT reveals evidence of intracranial hemorrhage
  • CT reveals significant mass effect with midline shift
  • Angiographic evidence of an arterial stenosis proximal to the occlusion that could prevent thrombus removal
  • Angiographic evidence of preexisting arterial injury
  • Life expectancy of less than 90 days
  • Participation in another clinical investigation that could confound the evaluation of the study device.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00334061


Locations
United States, Missouri
Saint Luke's Hospital
Kansas City, Missouri, United States, 64111
Sponsors and Collaborators
Penumbra Inc.
  More Information

Additional Information:
ClinicalTrials.gov Identifier: NCT00334061     History of Changes
Other Study ID Numbers: CLP 0676
First Submitted: June 2, 2006
First Posted: June 6, 2006
Results First Submitted: November 20, 2008
Results First Posted: January 12, 2009
Last Update Posted: July 29, 2009
Last Verified: December 2008

Keywords provided by Penumbra Inc.:
Penumbra
Ischemic
Stroke
Intervention
Neurovascular
Thrombus
Embolectomy
Ischemic stroke

Additional relevant MeSH terms:
Stroke
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases